The University of Southampton
University of Southampton Institutional Repository

Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma

Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma
Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma
Background: Few studies have investigated the use of specific immunotherapy (SIT) for childhood seasonal allergic asthma.
Objective: We sought to examine the efficacy and safety of SIT with Alutard SQ grass pollen (Phleum pratense Alutard SQ; ALK-Abelló, Hørsholm, Denmark) in children with seasonal allergic asthma.
Methods: A randomized, double-blind, placebo-controlled study assessing the efficacy of grass pollen SIT over 2 pollen seasons was performed. Children (3-16 years) with a history of seasonal allergic asthma sensitized to grass pollen (P pratense) and requiring at least 200 ?g of inhaled beclomethasone equivalent per day were enrolled. Subjects with symptomatic asthma or rhinoconjunctivitis outside the grass pollen season were excluded. The primary outcome measure was a combined asthma symptom-medication score during the second pollen season. Secondary outcome measures included end-point titration skin prick testing and conjunctival and bronchial provocation testing to allergen, sputum eosinophilia, exhaled nitric oxide, and adverse events.
Results: Thirty-nine subjects were enrolled. Thirty-five subjects provided data for analysis. The use of SIT was associated with a substantial reduction in asthma symptom-medication score compared with that after placebo (P = .04). There were also significant reductions in cutaneous (P = .002), conjunctival (P = .02), and bronchial (P = .01) reactivity to allergen after SIT compared with that after placebo. The 2 groups had similar levels of airway inflammation, despite a trend toward less inhaled steroid use in the active group. No serious adverse events were reported, and no subjects withdrew because of adverse events.
Conclusion: The study has shown that SIT is effective and well tolerated in children with seasonal allergic asthma to grass pollen.
seasonal allergic asthma, children, immunotherapy
0091-6749
263-268
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Hurley, Catriona
7ed3fff1-7a17-4763-a70f-4b7180b2bc7d
Turcanu, Victor
8cfa4bfb-3ef3-484d-8211-3572a1754185
Lack, Gideon
cac030a2-c358-4880-a91d-d67d06e8e321
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Hurley, Catriona
7ed3fff1-7a17-4763-a70f-4b7180b2bc7d
Turcanu, Victor
8cfa4bfb-3ef3-484d-8211-3572a1754185
Lack, Gideon
cac030a2-c358-4880-a91d-d67d06e8e321

Roberts, Graham, Hurley, Catriona, Turcanu, Victor and Lack, Gideon (2006) Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. Journal of Allergy and Clinical Immunology, 117 (2), 263-268. (doi:10.1016/j.jaci.2005.09.054).

Record type: Article

Abstract

Background: Few studies have investigated the use of specific immunotherapy (SIT) for childhood seasonal allergic asthma.
Objective: We sought to examine the efficacy and safety of SIT with Alutard SQ grass pollen (Phleum pratense Alutard SQ; ALK-Abelló, Hørsholm, Denmark) in children with seasonal allergic asthma.
Methods: A randomized, double-blind, placebo-controlled study assessing the efficacy of grass pollen SIT over 2 pollen seasons was performed. Children (3-16 years) with a history of seasonal allergic asthma sensitized to grass pollen (P pratense) and requiring at least 200 ?g of inhaled beclomethasone equivalent per day were enrolled. Subjects with symptomatic asthma or rhinoconjunctivitis outside the grass pollen season were excluded. The primary outcome measure was a combined asthma symptom-medication score during the second pollen season. Secondary outcome measures included end-point titration skin prick testing and conjunctival and bronchial provocation testing to allergen, sputum eosinophilia, exhaled nitric oxide, and adverse events.
Results: Thirty-nine subjects were enrolled. Thirty-five subjects provided data for analysis. The use of SIT was associated with a substantial reduction in asthma symptom-medication score compared with that after placebo (P = .04). There were also significant reductions in cutaneous (P = .002), conjunctival (P = .02), and bronchial (P = .01) reactivity to allergen after SIT compared with that after placebo. The 2 groups had similar levels of airway inflammation, despite a trend toward less inhaled steroid use in the active group. No serious adverse events were reported, and no subjects withdrew because of adverse events.
Conclusion: The study has shown that SIT is effective and well tolerated in children with seasonal allergic asthma to grass pollen.

This record has no associated files available for download.

More information

Published date: February 2006
Keywords: seasonal allergic asthma, children, immunotherapy

Identifiers

Local EPrints ID: 40650
URI: http://eprints.soton.ac.uk/id/eprint/40650
ISSN: 0091-6749
PURE UUID: f388aaf1-02d2-482c-b953-d596472304ff
ORCID for Graham Roberts: ORCID iD orcid.org/0000-0003-2252-1248

Catalogue record

Date deposited: 06 Jul 2006
Last modified: 16 Mar 2024 03:44

Export record

Altmetrics

Contributors

Author: Graham Roberts ORCID iD
Author: Catriona Hurley
Author: Victor Turcanu
Author: Gideon Lack

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×